Top 50 Pharma Tracker: eHCPs approve of new pharma trial data at ASCO 2023

Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.

The Top 50 Pharmaceutical Companies mentioned by eHCPs on Twitter

The latest insights from eHCPs mentioning the Top 50 Pharmaceutical Companies

The five pharmaceutical companies that were mentioned the most by eHCPs on Twitter in June 2023 were Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Lilly.

CREATION.co identified 10,305 eHCP mentions of pharmaceutical companies in June 2023, decreasing by slightly over 10% from the previous month.

ASCO 2023, which was held from 02 – 06 June, affected eHCP conversation at the start of the month, with eHCPs sharing trial data, presentations and opinions on the latest updates in their online posts. Among the top shared posts from ASCO 2023 was a post by genitourinary oncologist, Dr Toni Choueiri – who shared a thread relating to phase 3 trial data for treatment for renal cell carcinoma.

1/ Results from #CONTACT03 are out both @ASCO #ASCO23 and @TheLancet . The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type.
Kudos to @montypal, SC members, @roche, our patients, = for this phenomenal job. https://t.co/p7hYD4snXA pic.twitter.com/CXk1vqfB26

— Toni Choueiri, MD (@DrChoueiri) June 5, 2023

Dr Choueiri concluded the thread by stating that no benefit was found in this trial. However, he commended Roche for their contributions towards this and other trials, and for their efforts in assessing the efficacy of this treatment against other cancers.

10/ In conclusion, this the 1st ph3 clinical trial to show NO benefit of adding anti-PDL1 to targeted therapy beyond progression on PD1/L1 blockade, in patients with mRCC
Ongoing ph3 trials are testing the efficacy of IO rechallenge in other cancers including #HCC and #NSCLC

— Toni Choueiri, MD (@DrChoueiri) June 5, 2023

The next most shared post in the ASCO 2023 conversation was by Roger Olofsson Bagge, a professor in cancer surgery. He celebrated positive trial data for Moderna’s new mRNA cancer vaccine, highlighting his sentiments through emotive language on how the data was “so impressive that there is almost no need for phase III”. He was very pleased with the efforts by Moderna, and the important vaccine advancements made possible through mRNA technology.

Impressive data for @Moderna mRNA-4157 vaccine in 157 pts with melanoma stage IIIB-D/IV randomized to vaccine+pen to vs or bro alone. RFS HR 0.56 (p=0.03) and DMFS HR 0.35 (p=0.006)! So impressive that there is almost no need for phase III 🍾🍾🍾@ASCO #ASCO23 #MelSM pic.twitter.com/W9CQEL0dNM

— Roger Olofsson Bagge (@OlofssonBagge) June 5, 2023

Notably, HCPs also shared posts about pharma-HCP collaborations in health equity as seen in a post by Dr Estela Rodriguez, a thoracic oncologist. Dr Rodriguez shared a post demonstrating her collaboration with BMS in a workshop to address the disparities of trial inclusion, particularly with regard to Hispanic/Latino community members. 

#ASCO23 Starting early this morning at the #REAL @bmsnews workshop: Addressing Challenges of Hispanic/LatinX Inclusion in Clinical Trials with rising ⭐️ @mariagjMD @UCLAHealth @SylvesterCancer #clinicaltrialdiversity

⬇️ complexity of trials
⬆️ safety net hospitals… pic.twitter.com/duyhIoqvVD

— Dr. Estela Rodriguez (@Latinamd) June 3, 2023

Outside of the ASCO 2023 conversation, eHCPs engaged with data for Lilly’s new weight loss drug (retatrutide) – making Lilly this month’s fifth most mentioned company by HCPs online. eHCPs have reacted positively to retatrutide – with some eHCPs specifically highlighting data which demonstrated a significant 24% weight loss in 48 weeks.

@AniaJastreboff on @EliLillyandCo 's retatrutide data for #obesity

Just gonna let this sit here

⭐️24% #weightloss at just 48 wks
⭐️💯% with clinically significant #weightloss #ADARME #ADA2023 pic.twitter.com/EGXDsIzgY2

— Beverly G. Tchang, MD (@BevTchangMD) June 26, 2023

The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:

1. An article discussing a report for inconsistencies in COVID vaccine studies
2. An article referring to adverse events reported from vaccines.
3. A roundtable discussion for patients who have been hospitalised by COVID-19 – supported by an educational grant from Gilead.

In June, the 2023 list of the Top 50 pharmaceutical companies by Pharm Exec was updated. The new companies joining this list include Perrigo, Chugai Pharmaceutical, Horizon Therapeutics, BioNTech, Incyte, and Novavax. 

BioNTech came into the list as the 11th most mentioned pharmaceutical company by eHCPs. This was due to eHCPs sharing the news about BioNTech initiating an application with the EU regulator for an updated COVID vaccine to target Omicron subvariant XBB.1.5, as seen in this post by physician Dr Hank Schiffers.

Pfizer/BioNTech initiate application with EU regulator for updated COVID vaccine 👍 https://t.co/vCkb3Enn0v

— Dr.med.Hank Schiffers, MD, MBA, Lean Sensei (@leanhealth) June 24, 2023

CREATION.co continues to analyse online eHCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology notes:

• • In June 2023, CREATION Pinpoint® identified 10,305  healthcare professional authored tweets from 4,351 individual eHCPs mentioning a Top 50 Pharmaceutical company (according to revenue). 
  • Data for this research was analysed from the online Twitter conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 June and 30 June 2023.

• Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).

• In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
• Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In June 2023, 89 of these posts mentioned Janssen.

Click here to read the latest Top 50 tracker